{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.87","upperLimit":"2.33","value":"1.94"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"270"}],"units":"Participants"}],"title":"All treated participants"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.74","upperLimit":"2.00","value":"1.87"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"146"}],"units":"Participants"}],"title":"PD-L1 <1%"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.91","upperLimit":"3.71","value":"3.45"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"124"}],"units":"Participants"}],"title":"PD-L1 >= 1%"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.81","upperLimit":"2.04","value":"1.87"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"187"}],"units":"Participants"}],"title":"PD-L1 <5%"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.91","upperLimit":"5.52","value":"3.68"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"83"}],"units":"Participants"}],"title":"PD-L1 >=5%"}],"denoms":[{"counts":[{"groupId":"OG000","value":"270"}],"units":"Participants"}],"description":"PFS was defined as the time from first dosing date to the date of the first documented tumor progression, based on Blinded Independent Review Committee (BIRC) assessments or death due to any cause. Progression was defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions. PD-L1 expression level is defined as membranous staining in greater than or equal to 5% and greater than or equal to 1% tumor cells.","dispersionType":"95% Confidence Interval","groups":[{"description":"Nivolumab 3 mg/kg was administered as a 60 minute IV infusion Q2W","id":"OG000","title":"Nivolumab 3 mg/kg"}],"paramType":"MEDIAN","populationDescription":"All treated participants","reportingStatus":"POSTED","timeFrame":"From first dosing date to the date of the first documented tumor progression (up to approximately 6 months)","title":"Progression Free Survival (PFS)","type":"SECONDARY","unitOfMeasure":"Months"}